SCHEMBL5067583

SCHEMBL5067583

COc1ccccc1-c1nnc(-c2cc(C(F)(F)F)nn2C2CCN(C(=O)OC(C)(C)C)CC2)o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.47
JAK2 O60674 4/20 0.42
JAK3 P52333 4/20 0.42
PTK2 Q05397 4/20 0.42
TP53 P04637 4/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
CACNB4 O00305 1/20 0.41
CACNA1A O00555 1/20 0.41
CACNA1G O43497 1/20 0.41
CACNG3 O60359 1/20 0.41
CACNA1F O60840 1/20 0.41
CACNA1H O95180 1/20 0.41
CACNB3 P54284 1/20 0.41
CACNA2D1 P54289 1/20 0.41
CACNG7 P62955 1/20 0.41
CACNA1B Q00975 1/20 0.41
CACNA1D Q01668 1/20 0.41
CACNB1 Q02641 1/20 0.41
CACNG1 Q06432 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5064402 0.84 CARM1 (0.44) CARM1TP53HPGDTSHRALDH1A1
SCHEMBL5067032 0.83 PLAT (0.47) CARM1TP53HPGDTSHRALDH1A1
SCHEMBL5069695 0.79 CARM1 (0.45) CARM1TP53HPGDCACNA1GALDH1A1
SCHEMBL14012649 0.76 GPR119 (0.51) TSHRTGFBR1MAPTGPR119
SCHEMBL14012650 0.74 CARM1 (0.50) CARM1TP53
SCHEMBL24007611 0.72 STS (0.49) MAPTGPR119
SCHEMBL5070408 0.72 GPR119 (0.48) JAK2TSHRTGFBR1PIK3CDPIK3R2
SCHEMBL5070409 0.72 GPR119 (0.48) JAK2TSHRTGFBR1PIK3CDPIK3R2
SCHEMBL5066894 0.71 STS (0.46) MAPTMEN1KMT2AGPR119
SCHEMBL5070485 0.71 CARM1 (0.49) CARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338437-B2 Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy METHYLGENE INC. (CA) 2012-12-25 US disclosed
US-8338437-B2 Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy METHYLGENE INC. (CA) 2012-12-25 US disclosed
US-8338437-B2 Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy METHYLGENE INC. (CA) 2012-12-25 US disclosed
US-20080280925-A1 Amines as Small Molecule Inhibitors METHYLGENE INC. 2008-11-13 US disclosed
US-20080280925-A1 Amines as Small Molecule Inhibitors METHYLGENE INC. 2008-11-13 US disclosed
US-20080280925-A1 Amines as Small Molecule Inhibitors METHYLGENE INC. 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280925-A1 Amines as Small Molecule Inhibitors CARM1, PRMT1, PRMT3 CARM1 1/4885JAK2 2220/4885JAK3 2543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.